Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Marco Matucci-Cerinic, Cosimo Bruni, Yannick Allanore, Massimo Clementi, Lorenzo Dagna, Nemanja S. Damjanov, Amato De Paulis, Christopher P. Denton, Oliver Distler, David Fox, Daniel E. Furst, Dinesh Khanna, Thomas Krieg, Masataka Kuwana, Eun Bong Lee, Mengtao Li, Shiv Pillai, Yukai Wang, Xiaofeng Zeng, Gloria Taliani

Research output: Contribution to journalArticlepeer-review

Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.

Original languageEnglish
Pages (from-to)S724-S726
JournalAnnals of the Rheumatic Diseases
Volume79
Issue number6
DOIs
Publication statusPublished - Jun 1 2020

Keywords

  • autoimmune diseases
  • hydroxychloroquine
  • scleroderma
  • systemic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management'. Together they form a unique fingerprint.

Cite this